Nicola Shaw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nicola Shaw has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
D. Peckham
8 shared publicationsC. Etherington
6 shared publicationsK. Pollard
Regional Adult CF Centre, St James's University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom; Department of Physiotherapy, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom
4 shared publicationsP. Whitaker
4 shared publicationsG. Spoletini
Regional Adult CF Centre, St James's University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom
3 shared publicationsH. White
Adult CF Unit, St. James's Hospital, Leeds, LS9 7TF, UK
3 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Elsevier in Journal of Cystic Fibrosis
Medication burden among adults with cystic fibrosis prescribed CFTR Modulators: a cross-sectional survey
- 13 November 2026
- Published by Elsevier in Journal of Cystic Fibrosis
Open AccessMedication burden among adults with cystic fibrosis prescribed CFTR Modulators: a cross-sectional survey
- Top Cited PapersOpen Access
- 16 May 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (6) , 1061-1065
Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis
- 16 May 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (6) , 1061-1065
Top Cited PapersOpen AccessDose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis
- 1 June 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18, S9
WS05-2 Empowering patients with cystic fibrosis to participate in the administration of intravenous antibiotics in hospital
- 1 June 2019
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 18, S9
WS05-2 Empowering patients with cystic fibrosis to participate in the administration of intravenous antibiotics in hospital
- 11 January 2019
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 74 (5) , 1425-1429
Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series
The efficacy of antibiotic treatment in pulmonary and systemic infections in cystic fibrosis (CF) is limited by the increased prevalence of MDR strains of Pseudomonas aeruginosa and Burkholderia cepacia complex. Ceftazidime/avibactam is a new combination which, in vitro, appears to have good activity against MDR strains of P. aeruginosa and B. cepacia complex. A retrospective analysis was performed including adult patients with CF who received at least one course of ceftazidime/avibactam owing to pulmonary exacerbations not responding to conventional antibiotic treatment. Treatment with ceftazidime/avibactam was associated with reduction in inflammatory markers and improvement in lung function. No episodes of acute kidney injury or elevation in transaminase were observed. Ceftazidime/avibactam appeared to be well tolerated and improved patients' outcomes. Further studies are needed to better assess the role of this new combination in CF.
- 11 January 2019
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 74 (5) , 1425-1429
Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series
The efficacy of antibiotic treatment in pulmonary and systemic infections in cystic fibrosis (CF) is limited by the increased prevalence of MDR strains of Pseudomonas aeruginosa and Burkholderia cepacia complex. Ceftazidime/avibactam is a new combination which, in vitro, appears to have good activity against MDR strains of P. aeruginosa and B. cepacia complex. A retrospective analysis was performed including adult patients with CF who received at least one course of ceftazidime/avibactam owing to pulmonary exacerbations not responding to conventional antibiotic treatment. Treatment with ceftazidime/avibactam was associated with reduction in inflammatory markers and improvement in lung function. No episodes of acute kidney injury or elevation in transaminase were observed. Ceftazidime/avibactam appeared to be well tolerated and improved patients' outcomes. Further studies are needed to better assess the role of this new combination in CF.
- Open Access
- 1 June 2018
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 50, 82-87
Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre
- 1 June 2018
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 50, 82-87
Open AccessIntravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre
- 8 March 2017
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 49 (3) , 1600987
Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis
The aim of this study was to characterise adherence in an adult population with cystic fibrosis (CF) and to investigate if variation in lung function was a predictor of adherence to treatment.The adherence of patients aged ≥16 years from an adult CF centre was measured by medication possession ratio (MPR) and self-report. Patients were assigned to one of three adherence categories (1), weight and C-reactive protein concentration, measured from 6 months and 12 months before baseline.MPR data for 106 of 249 patients (mean age 29.8±9.2 years) was retrieved, indicating a mean adherence of 63%. The coefficient of variation for FEV1was inversely related to adherence and was a univariate predictor of adherence (6 months: OR 0.92, 95% CI 0.87–0.98, p=0.005; 12 months: OR 0.94, 95% CI 0.93–0.99, p=0.03) and remained significant in the final models. The coefficient of variation of weight and C-reactive protein were not predictive of adherence.The coefficient of variation of FEV1was identified as an objective predictor of adherence. Further evaluation of this potential marker of adherence is now required.
- 8 March 2017
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 49 (3) , 1600987
Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis
The aim of this study was to characterise adherence in an adult population with cystic fibrosis (CF) and to investigate if variation in lung function was a predictor of adherence to treatment.The adherence of patients aged ≥16 years from an adult CF centre was measured by medication possession ratio (MPR) and self-report. Patients were assigned to one of three adherence categories (1), weight and C-reactive protein concentration, measured from 6 months and 12 months before baseline.MPR data for 106 of 249 patients (mean age 29.8±9.2 years) was retrieved, indicating a mean adherence of 63%. The coefficient of variation for FEV1was inversely related to adherence and was a univariate predictor of adherence (6 months: OR 0.92, 95% CI 0.87–0.98, p=0.005; 12 months: OR 0.94, 95% CI 0.93–0.99, p=0.03) and remained significant in the final models. The coefficient of variation of weight and C-reactive protein were not predictive of adherence.The coefficient of variation of FEV1was identified as an objective predictor of adherence. Further evaluation of this potential marker of adherence is now required.
- 1 December 2014
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 13 (6) , 681-686
The development and deployment of integrated electronic care records in a regional adult and paediatric cystic fibrosis unit
- 1 December 2014
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 13 (6) , 681-686
The development and deployment of integrated electronic care records in a regional adult and paediatric cystic fibrosis unit
- 1 June 2014
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 13, S117
273 Relationship between self-reported adherence, medication collections and clinical variation in cystic fibrosis
- 1 June 2014
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 13, S117
273 Relationship between self-reported adherence, medication collections and clinical variation in cystic fibrosis
- 1 June 2014
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 13, S22
WS10.6 Objective predictors of self-report of adherence in adults with cystic fibrosis
- 1 June 2014
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 13, S22
WS10.6 Objective predictors of self-report of adherence in adults with cystic fibrosis